期刊文献+

拓扑替康治疗复发性晚期肿瘤毒副作用的护理

下载PDF
导出
摘要 目的探讨拓扑替康(TPT)治疗复发性晚期肿瘤的临床疗效和毒副作用的护理。方法复发性晚期肿瘤患者30例,可评价疗效和毒副作用者29例,其中小细胞肺癌10例,卵巢癌6例,非小细胞肺癌3例,食道癌3例,胃癌3例、十二指肠癌2例,结肠癌3例。均采用TPT联合顺铂或氟尿嘧啶治疗,TPT1.2mg·m-2·d-1,静脉滴注,d1~d5,21d为一周期。结果可评价疗效的29例中,完全缓解(CR)2例,部分缓解(PR)7例,有效率(RR)31.0%。主要毒副作用是骨髓抑制,表现为白细胞减少为主,经过精心护理,无严重并发症发生。非血液学毒性较轻。结论TPT是治疗复发性晚期肺癌、卵巢癌、消化系肿瘤有效的药物。主要的剂量限制毒性是骨髓抑制,应有针对性实施护理。
作者 王先爱
出处 《安徽医药》 CAS 2005年第5期390-391,共2页 Anhui Medical and Pharmaceutical Journal
  • 相关文献

参考文献6

二级参考文献21

  • 1李国栋.拓朴异构酶特性与肿瘤细胞的耐药性[J].河南肿瘤学杂志,1996,9(4):317-319. 被引量:72
  • 2[1]Schiller JH. Topotecan in small cell lung cancer[J].Semin Oncol,1997,24(6 Suppl 20):27-33.
  • 3[2]Mitsui I,Kumazawa E,Hirota Y,et al. A new water-soluble camptothecin derivative,DX-8951f,exhibit potent antitumor activity against human tumors in VITRO and in VIVO[J].Jpn J Cancer Res,1995,86(8):776-782.
  • 4[3]Jonsson E,Fridborg H,Csoka K,et al. Cytotoxic activity of topotecan in human tumor cells from patients[J].Br J Cancer,1997,76(2):211-219.
  • 5[4]Roth BJ,Johnson DH,Einhom LH,et al. Randomized study of cyclophosphamide,doxorubicin,and vincristine versus etoposide and cisplatin versus altemation of these two regimens in extensive small-cell lung cancer:a phase Ⅲ trial of southeastern Cancer Study Group[J].J Clin Oncol,1992,10(2):282-291.
  • 6[5]Shepherd FA,Evans WK,Mac Comick R,et al. Cyclophosphamide,doxorubicin,and vincristine in etoposide and cisplatin-resistant small cell lung cancer[J].Cancer Treat Rep,1987,71(10):941-944.
  • 7[6]Schiller JH,Kim K,Hutson P,et al. Rhase Ⅱ study of topotecan in patients with extensive-stage small-cell carcinoma of the lung:an Eastern cooperative Oncology Group Trail[J].J Clin Oncol,1996,14(8):2345-2352.
  • 8[7]Von Pawel J,Schiller JH,Shepherd FA,et al. Topotecan versus cyclophosphamide,doxorubicin,and vincristine for the treatment of recurrent small-cell lung cancer[J].J Clin Oncol,1999,17(2):658-667.
  • 9[8]Rowinsky EK,Grochow LB,Bendricks CB,et al. Phase I and pharmacologic study of topotecan:a novel topoisomerase I inhibitor[J].J Clin Oncol,1992,10(4):647-656.
  • 10[9]Kollmannsberger C,Mross K,Jakob A,et al. Topotecan-A novel topoisomerase I inhibitor:pharmacology and clinical experience[J].Oncology,1999,56(1):1-12.

共引文献133

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部